Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Clover Biopharmaceuticals Ltd. ( (HK:2197) ).
Clover Biopharmaceuticals Ltd. has initiated a Phase I clinical trial for its new respiratory combination vaccine candidates, SCB-1022 and SCB-1033, which target RSV, hMPV, and PIV3. This trial follows promising results from a previous study comparing Clover’s RSV PreF vaccine candidate to GSK’s AREXVY, indicating a strong immunogenicity and tolerability profile. The ongoing trial will enroll up to 192 older adults to assess the safety, reactogenicity, and immunogenicity of these new vaccine candidates, potentially strengthening Clover’s position in the vaccine market.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of innovative vaccines. The company utilizes its proprietary Trimer-Tag vaccine technology platform to create subunit vaccine antigens, targeting respiratory diseases such as RSV, hMPV, and PIV3.
Average Trading Volume: 1,448,367
Technical Sentiment Signal: Hold
Current Market Cap: HK$337.2M
For an in-depth examination of 2197 stock, go to TipRanks’ Overview page.